E-DRUG: Independent Drug and Healthcare Newsletter for June 2021
-------------------------------------------------------------------
Newsletter, June 2021
Independent information by and for healthcare professionals
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International : Prescrire IN ENGLISH - Offers - Subscribe now, or renew subscription - <span style="font-size:13px">Subscribe or renew online</span>
In Prescrire's Spotlight this month :
----------------------------------------------------------------------------
FEATURED REVIEW
Oral semaglutide (Rybelsus°): more uncertainty than with subcutaneous liraglutide.
Semaglutide was first authorised in the European Union as a solution for weekly subcutaneous injection. It was authorised more recently in oral tablet form.
How do Prescrire's editors rate this new product?
Read more
----------------------------------------------------------------------------
FREE DOWNLOAD
In the June issue of Prescrire International: Non-metastatic, castration-resistant prostate cancer
Survival extended with the addition of apalutamide or enzalutamide. Full text available for free download.
Read more
----------------------------------------------------------------------------
EDITORIAL
Covid-19 drugs and vaccines: big money and winning alliances
The market for covid-19 drugs and vaccines is huge, involving billions of patients, with tens of billions of dollars potentially up for grabs. Business as usual? Not quite.
Read more
----------------------------------------------------------------------------
Iodine during pregnancy: supplementation should not be systematic
Iodine-containing food supplements have no proven benefits for pregnant women, and can be dangerous for the unborn child.
Read more
----------------------------------------------------------------------------
Oral cancer drugs: care provided in community pharmacies
Community pharmacists in France can offer, and claim payment for, structured pharmaceutical care for the growing number of patients taking oral cancer drugs.
Read more
----------------------------------------------------------------------------
Memantine (Ebixa° and other brands): perception disorders
Memantine is a drug with psychotropic actions, misuse of which can become problematic, leading, in particular, to dissociative disorders which are not always effects being sought by the user.
Read more
----------------------------------------------------------------------------
Pre-exposure prophylaxis for HIV (PrEP): reduction in risk of infection confirmed
For patients at high risk of infection by the HIV virus, evaluation has confirmed the efficacy of PrEP using a combination of emtricitabine + tenofovir disoproxil (Truvada° and other brands).
Read more
----------------------------------------------------------------------------
Prescrire: independence and transparency, in the name of better patient care
The independent French medical journal Prescrire is produced by healthcare professionals who strive to protect medical information and continuing education from the contradictory influences at play in the medico-pharmaceutical arena.
Read more
----------------------------------------------------------------------------
Waste in covid-19 clinical trials
The covid-19 pandemic has given rise to a large number of clinical trials evaluating a wide range of therapeutic avenues, but not all are worthwhile.
Read more
---------------------------------------------------------------------------
France's Mediator° trial: Servier and the French drug regulatory agency convicted and sentenced
There will be appeal proceedings.
Read more
----------------------------------------------------------------------------
COMING SOON
Solriamfetol and drowsiness due to narcolepsy or sleep apnoea Tezacaftor + ivacaftor and cystic fibrosis. Limiting the use of proton-pump inhibitors. Human papillomavirus vaccine in men. Dietary supplements: poorly evaluated and poorly monitored...
Subscribe now
Prescrire International <international@prescrire.org>